Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615563 · ClinicalTrials.gov registry record
Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 246
- Enrollment target
NCT00615563 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 246 participants.
The verdict
NCT00615563 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 246 participants
- Enrollment target
Study Summary
The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen.
Interventions
- BEHAVIORAL NO BI Drug administered
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615563
The ClinicalTrials.gov registry entry for NCT00615563 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NO BI Drug administered is the first listed.
NCT00615563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615563 about?
NCT00615563 is a clinical study titled "Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)". The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently fai...
What is the current status of trial NCT00615563?
This trial is currently completed. The enrollment target is 246 participants. The study started on 2007-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00615563?
The interventions under investigation include: NO BI Drug administered (BEHAVIORAL).
Who is sponsoring clinical trial NCT00615563?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.